Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 180 results found since Jan 2013.

Evaluation of Inflow Cannulation Site for Implantation of Right‐Sided Rotary Ventricular Assist Device
Abstract Right heart dysfunction is one of the most serious complications following implantation of a left ventricular assist device, often leading to the requirement for short‐ or long‐term right ventricular assist device (RVAD) support. The inflow cannulation site induces major hemodynamic changes and so there is a need to optimize the site used depending on the patient's condition. Therefore, this study evaluated and compared the hemodynamic influence of right atrial cannulation (RAC) and right ventricular cannulation (RVC) inflow sites. An in vitro variable heart failure mock circulation loop was used to compare RA...
Source: Artificial Organs - April 29, 2013 Category: Transplant Surgery Authors: Shaun D. Gregory, Mark J. Pearcy, John Fraser, Daniel Timms Tags: Main Text Article Source Type: research

Impact of Pump Replacement on Outcome in Advanced Heart Failure Patients With Left Ventricular Assist System
In conclusion, pump replacement for thrombus formation may have a strong association with worse outcome. Our results reconfirm the clinical importance of device thrombus in the management of LVAS.
Source: Artificial Organs - May 20, 2013 Category: Transplant Surgery Authors: Yoshio Iwashima, Masanobu Yanase, Takeshi Horio, Osamu Seguchi, Yoshihiro Murata, Tomoyuki Fujita, Koichi Toda, Yuhei Kawano, Takeshi Nakatani Tags: Main Text Article Source Type: research

248 * long-term circulatory support with rotary blood pumps: is it worthwhile?
Conclusions: Patients on long-term support have an excellent haemodynamic profile and show an acceptable risk-benefit ratio. Although heart transplantation remains the ultimate target at present, our data show that long-term circulatory support is a viable option with the potential to become a more permanent solution in the long-term.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Capoccia, M., Sabashnikov, A., Mohite, P. N., Garcia Saez, D., Zych, B., Hards, R., Bowles, C. T., Moza, A., De Robertis, F., Bahrami, T., Amrani, M., Banner, N. R., Simon, A. R. Tags: Left ventricular assist devices II: Long-term support Source Type: research

Anticoagulation with a new oral anticoagulant in heart transplant recipients
Rivaroxaban is now accepted for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, and treatment and secondary prevention of deep vein thrombosis and pulmonary embolism. Nothing is known about the use of this new anticoagulant in transplanted patients. Here we report a series of heart transplant recipients treated with rivaroxaban and followed at our transplantation center.
Source: International Journal of Cardiology - July 25, 2013 Category: Cardiology Authors: Pierre Ambrosi, Bernard Kreitmann, William Cohen, Gilbert Habib, Pierre Morange Tags: Letters to the Editor Source Type: research

Use of Left Ventricular Assist Device (HeartMate II): A Singapore Experience
We report our experience with the HeartMate II (HMII) LVAD (Thoratec Corporation, Pleasanton, CA, USA) as a bridge‐to‐heart transplant in our center from 2009 to 2012. This was a retrospective review of 23 consecutive patients who underwent HMII LVAD implantation in our center between May 2009 and December 2012. All patients were classified as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1 to 3 and underwent LVAD implantation as a bridge‐to‐heart transplant. There were 17 male and 6 female patients. The mean age was 43.6 years old (range 14 to 64). The etiologies of heart fa...
Source: Artificial Organs - January 7, 2014 Category: Transplant Surgery Authors: Choon Pin Lim, Cumaraswamy Sivathasan, Teing Ee Tan, Chong Hee Lim, Ka Lee Kerk, David Kheng Leng Sim Tags: Main Text Article Source Type: research

Hemolysis: A harbinger of adverse outcome after left ventricular assist device implant
Background: The clinical relevance of elevated serum markers of hemolysis during left ventricular assist device (LVAD) support has not been fully ascertained.Methods: Lactate dehydrogenase (LDH) and serum free hemoglobin (sfHg) values were tallied monthly in 182 patients on HeartMate II (Thoratec, Pleasanton, CA) LVAD support. Peak values for each marker were identified, and 2 hemolysis definitions were applied to the cohort: Hemolysis according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria (sfHg> 40 mg/dl with signs/symptoms) and/or hemolysis defined by an LDH ≥ 600 IU/liter ...
Source: The Journal of Heart and Lung Transplantation - December 2, 2013 Category: Transplant Surgery Authors: Jennifer A. Cowger, Matthew A. Romano, Palak Shah, Neha Shah, Vivek Mehta, Jonathan W. Haft, Keith D. Aaronson, Francis D. Pagani Tags: Featured Articles Source Type: research

Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device
Background: Modern left ventricular assist devices (LVAD) require anti-coagulation (AC) with warfarin and anti-platelet therapy to prevent thromboembolic complications in patients. Gastrointestinal bleeding (GI) is a significant adverse event in these patients and treatment typically requires reduction or elimination of AC or anti-platelet therapy. It is not known whether alterations in AC to treat GI bleeding influence subsequent risk of thromboembolic (TE) events during LVAD support.Methods: Between July 2003 and September 2011, 389 patients (308 male) underwent implantation of a continuous-flow LVAD at the University of...
Source: The Journal of Heart and Lung Transplantation - September 9, 2013 Category: Transplant Surgery Authors: John M. Stulak, Dustin Lee, Jonathon W. Haft, Matthew A. Romano, Jennifer A. Cowger, Soon J. Park, Keith D. Aaronson, Francis D. Pagani Tags: Featured Articles Source Type: research

Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation
Conclusions: LMWH in the setting of LVAD shows rapid and constant biologic efficacy. Anti-coagulation with LMWH appears feasible after LVAD implantation. These findings support further evaluation of LMWH as an alternative to unfractionated heparin in this patient cohort.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: Sigrid E. Sandner, Julia Riebandt, Thomas Haberl, Stephane Mahr, Angela Rajek, Heinrich Schima, George M. Wieselthaler, Guenther Laufer, Daniel Zimpfer Tags: Featured Articles Source Type: research

Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support
Mechanical circulatory support (MCS) with a continuous-flow (CF) rotary pump is associated with low levels of hemolysis during normal pump operation. Clinically significant hemolysis can be an early sequelae of pump thrombus. Left ventricular assist device (LVAD) thrombosis may result in stroke, peripheral embolism, heart failure, device exchange, and death. The timely detection of pump thrombus remains challenging.
Source: The Journal of Heart and Lung Transplantation - August 21, 2013 Category: Transplant Surgery Authors: Palak Shah, Vivek M. Mehta, Jennifer A. Cowger, Keith D. Aaronson, Francis D. Pagani Tags: Research Correspondence Source Type: research

Incidence of increases in pump power use and associated clinical outcomes with an axial continuous-flow ventricular assist device
Left ventricular assist devices (LVADs) have been shown to improve survival in patients with end-stage heart failure. Newer-generation LVADs with continuous-flow mechanics yield lower rates of disabling stroke, infection, and need for device exchange compared with earlier pulsatile-flow devices. It has been hypothesized that an elevation in the pump power may be an early indication of device thrombosis. Our goal was to define the frequency of pump power elevations, evaluate when they happen in relation to device implantation, and determine the rate at which they precede adverse events suggestive of pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - January 1, 2014 Category: Transplant Surgery Authors: Robert J. Steffen, Edward G. Soltesz, Kimberly Miracle, Sangjin Lee, Maria Mountis, Nader Moazami Tags: Research Correspondence Source Type: research

Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices
Conclusions: In the setting of LVAD thrombosis, thrombolytic therapy is an alternate treatment strategy in a subset of patients. Candidacy for this alternate procedure must carefully weigh the risks of complications, including hemorrhage and thromboembolism.
Source: Journal of Cardiac Failure - December 19, 2013 Category: Cardiology Authors: Kelly Schlendorf, Chetan B. Patel, Thomas Gehrig, Todd L. Kiefer, G. Michael Felker, Adrian F. Hernandez, Laura J. Blue, Carmelo A. Milano, Joseph G. Rogers Tags: Clinical Investigations Source Type: research

Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices
Background: Continuous-flow left ventricular assist devices (LVADs) expose blood cells to high shear stress, potentially resulting in the production of microparticles that express phosphatidylserine (PS+) and promote coagulation and inflammation. In this prospective study, we attempted to determine whether PS+ microparticle levels correlate with clinical outcomes in LVAD-supported patients.Methods: We enrolled 20 patients undergoing implantation of the HeartMate II LVAD (Thoratec Corp, Pleasanton, CA) and 10 healthy controls who provided reference values for the microparticle assays. Plasma was collected before LVAD implan...
Source: The Journal of Heart and Lung Transplantation - January 21, 2014 Category: Transplant Surgery Authors: Angelo Nascimbene, Ruben Hernandez, Joggy K. George, Anita Parker, Angela L. Bergeron, Subhashree Pradhan, K. Vinod Vijayan, Andrew Civitello, Leo Simpson, Maria Nawrot, Vei-Vei Lee, Hari R. Mallidi, Reynolds M. Delgado, Jing Fei Dong, O.H. Frazier Tags: Featured Articles Source Type: research

Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research

High early cardiovascular mortality following liver transplantation
Abstract Cardiovascular disease (CVD) contributes to excess long‐term mortality after liver transplantation (LT), however little is known about early post‐operative CVD mortality in the current era. In addition, there is no model to predict early post‐operative CVD mortality across centers. We analyzed adult recipients of primary LT in the Organ Procurement and Transplantation Network (OPTN) database between February 2002 and December 2012 to assess prevalence and predictors of early (30‐day) CVD mortality, defined as death from arrhythmia, heart failure, myocardial infarction, cardiac arrest, thromboembolism, and/...
Source: Liver Transplantation - July 5, 2014 Category: Transplant Surgery Authors: Lisa B. VanWagner, Brittany Lapin, Josh Levitsky, John T. Wilkins, Michael M. Abecassis, Anton I. Skaro, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events
The aim of this study was to evaluate the prevalence of early pump power elevation events in patients with the HeartMate II (HMII) and its impact on subsequent development of stroke and pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - March 3, 2014 Category: Transplant Surgery Authors: Christopher T. Salerno, Kartik S. Sundareswaran, Thomas P. Schleeter, Sina L. Moanie, David J. Farrar, Mary Norine Walsh Tags: Featured Articles Source Type: research